Skip to main content

Table 1 Performance of the CD8xPD-L1 signature, its components, and manual PD-L1 scoring in durvalumab-treated patients

From: Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Measure Group (n) Prevalence PPV
(95% CI)
Median OS, months
(95% CI)
OS p-value Median PFS, months
(95% CI)
PFS p-value
Training Set (n = 84)
 CD8xPD-L1 positive (26) 0.31 0.42 (0.23–0.63) 18.9 (8.2–NR) 0.024 5.3 (2.6–9.3) 0.00042
negative (58) 0.69 0.09 (0.03–0.19) 8.9 (4.1–12.9) 1.4 (1.2–1.4)
 CD8+ cell density high (32) 0.38 0.34 (0.19–0.53) 18.9 (12.9–NR) 0.012 4.4 (1.4–7.6) 0.00045
low (52) 0.62 0.10 (0.03–0.21) 8.8 (4.3–11.1) 1.4 (1.2–2.3)
 PD-L1+ cell density high (26) 0.31 0.39 (0.20–0.59) 18.9 (5.6–NR) 0.071 4.7 (1.6–7.6) 0.023
low (58) 0.69 0.10 (0.04–0.21) 8.9 (4.1–13.1) 1.4 (1.3–1.7)
 PD-L1 TC ≥25% (49) 0.58 0.29 (0.17–0.43) 17.9 (8.9–NR) 0.018 2.8 (1.4–5.3) 0.0048
< 25% (35) 0.42 0.06 (0.01–0.19) 7.6 (3.4–12.9) 1.4 (1.2–1.4)
Test Set (n = 79)
 CD8xPD-L1 positive (33) 0.42 0.36 (0.20–0.55) 24.2 (14.5–NR) 0.00011 7.3 (3.1–9.8) 0.00095
negative (46) 0.58 0.07 (0.01–0.18) 6.5 (4.2–9.8) 2.6 (1.4–3.9)
 CD8+ cell density high (42) 0.53 0.24 (0.12–0.40) 20.3 (14.0–27.8) 0.0044 5.5 (3.1–9.2) 0.0054
low (37) 0.47 0.14 (0.05–0.29) 6.5 (3.6–9.8) 2.5 (1.4–4.1)
 PD-L1+ cell density high (29) 0.37 0.38 (0.21–0.58) 24.3 (6.5–NR) 0.045 7.3 (2.6–9.2) 0.087
low (50) 0.63 0.08 (0.02–0.19) 9.3 (6.0–15.5) 2.8 (1.7–5.2)
 PD-L1 TC ≥25% (47) 0.59 0.28 (0.16–0.43) 15.5 (7.7–24.2) 0.19 4.8 (2.6–7.3) 0.25
< 25% (32) 0.41 0.06 (0.01–0.21) 7.8 (5.7–15.5) 2.8 (1.4–6.5)
  1. Abbreviations: CD8 Cluster of differentiation 8, CI Confidence interval, NR Not reached, OS Overall survival, PD-L1 Programmed death ligand-1, PFS Progression-free survival, PPV Positive predictive value, TC Tumor cell